Immunotherapy of advanced stage, invariably drug-resistant cancers expressing ectopically hCG
| Autor: | Hemant K. Vyas, Jagdish C. Gupta, G.P. Talwar, Shilpi Puruswani, R. S. Kabeer |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
endocrine system
biology urogenital system Angiogenesis business.industry medicine.medical_treatment Cancer Embryo Immunotherapy medicine.disease Embryonic stem cell Human chorionic gonadotropin medicine biology.protein Cancer research Antibody business reproductive and urinary physiology hormones hormone substitutes and hormone antagonists Hormone |
| DOI: | 10.1016/b978-0-12-820050-6.00026-6 |
| Popis: | Human chorionic gonadotropin (hCG) is normally made by the early embryo soon after fertilization of the egg. It plays a vital role in the implantation of embryos and in sustenance of pregnancy. Neither nonpregnant females nor healthy males make this hormone. However, a number of publications have appeared in literature reporting the unexpected synthesis and secretion of hCG by advanced stage cancers in both males and females. Almost all types of cancers secrete hCG. Invariably the expression of hCG/subunits takes place at an advanced stage of cancer. The prognosis of such cancers is poor, and it appears that the dedifferentiation of cells goes to a stage that they become like embryonic cells, thereby expressing proteins such as hCG, as such hCG is considered a promoter of invasiveness and angiogenesis in cancer that produce it. This chapter describes a potential immunotherapy against hCG expressing cancer and describes the work in progress to humanize an antibody for eventual use to treat cancer in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|